Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Herceptin Hylecta

(her-SEP-tin hy-LEK-tuh)
A combination of trastuzumab and hyaluronidase used alone or with other drugs to treat adults with certain types of HER2-positive breast cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows trastuzumab to be given by injection under the skin. Herceptin Hylecta can be given in less time than trastuzumab alone, which is given as an infusion. Also called trastuzumab and hyaluronidase.
More Information
Search NCI's Dictionary of Cancer Terms